INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10578385	
	Filing Date		2007-05-11	
	First Named Inventor	Josep	oh J. Barchi, Jr.	
	Art Unit		1614	
	Examiner Name	Not Y	et Assigned	
	Attorney Docket Numb	er	NIHA-0278	

	U.S.PATENTS								
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5879715		1999-03-09	Hernandez, et al.				
	2	6361944	B1	2002-03-26	Mirkin, et al.				
	3	6530944	B2	2003-03-11	West, et al.				
	4	6602932	B2	2003-08-05	Feldheim, et al.				
	5	4853335		2989-08-01	Olsen, et al.				
If you wisl	n to ac	ld additional U.S. Paten		·	ease click the Add button.				
			U.S.P	ATENT APPLIC	CATION PUBLICATIONS				
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20040052729	A1	2004-03-18	Penades, et al.				

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10578385
Filing Date		2007-05-11
First Named Inventor Josep		oh J. Barchi, Jr.
Art Unit		1614
Examiner Name	Not Y	et Assigned
Attorney Docket Number		NIHA-0278

	2	20040018633	A1	2004-01-29		Foos, et al.				
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Add	butto	on.	
				FOREIG	SN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	<b>T</b> 5
	1	200232404	wo		A3	2002-04-25	Consejo Superior D Investigaciones Cientificas	e		
	2	2005046722	wo		A3	2005-05-26	The Government of the United States of America			
	3	2471920	CN		A1	2004-06-28	Fraunhofer-Gesells Zur Foerderung Der Angewan			
If you wis	h to ac	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	buttor	า	
			NON	I-PATEI	NT LITE	RATURE DO	CUMENTS			
Examiner Initials*  Cite No  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								<b>T</b> 5		
	1	SPRINGER, G.F., "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy," J. Mol. Med., 1997, 75, 594-602								
	2	GLINKSY, V.V., ET AL., "The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium," Cancer Res., 2001, 61(12), 4851-4857								
	3	HAKOMORI, "Aberrant of 52,257-331	glycosyla	tion in tur	nors and	l tumor-associa	ted carbohydrate anti	gens,"	Adv. Cancer Res., 1989,	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10578385		
Filing Date		2007-05-11		
First Named Inventor Josep		h J. Barchi, Jr.		
Art Unit		1614		
Examiner Name	Not Y	et Assigned		
Attorney Docket Number		NIHA-0278		

4 SVAROVSKY, S.A., ET AL., "Highly efficient preparation of Lumor antilgen-containing glycopeptide building blocks from novel pentenyl glycosides," Carbohydr. Rs., 2003, 338, 1925-1935  5 BRUST, ET AL., "Synthesis of thiol-derivatized gold nanoparticles in a two-phase liquid-liquid system," J. Chem. Soc    6 PALE-GROSDEMANGE, C., ET AL., "Formation of self-assembled monolayers by chemisorption of derivatives of oligo    7 CTSUKA, H., ET AL., "Quantitative and reversible lectin-induced association of gold nanoparticles modified with a-    8 BARCHI, J.J., JR., ET AL., "Synthesis and properties of carbohydrate- and glycopeptide-bearing nanoparticles," 226th    9 GLINSKY, V.V., ET AL., "Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment    10 KHALDOYANIDI, S.K., ET AL., "MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions," 2003, 278(6), 4127-4134    11 RAGUPATHI G., ET AL., "Vaccines prepared with siably-Tn and sialy-Tn trimers using the 4-(4-materindomethyl) cyclohexane-1 carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary much and aialy-Tn positive tumor cells," Cancer Immunology Immunotherapy, 1998, 46(1), 1-8    12 LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8),    13 SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivelent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2),    14 GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,			
Chem. Commun., 1994, 801-802    Chem. Commun., 1994, 801-802	4		
OTSUKA, H., ET AL., "Quantitative and reversible lectin-induced association of gold nanoparticles modified with a- Lactosyl_ J. Am. Chem. Soc., 2001, 123(34), 8226-8230  BARCHI, J.J., JR., ET AL., "Synthesis and properties of carbohydrate- and glycopeptide-bearing nanoparticles," 226th Am. Chem. Soc., National Meeting, NY, Abstracts of Papers, 2003, Part 1, ISSN: 0065-7727, page 40  GLINSKY, V.V., ET AL., "Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium," Cancer Res., 2003, 63(13), 3805-3811  KHALDOYANIDI, S.K., ET AL., "MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions," 2003, 278(6), 4127-4134  RAGUPATHI G., ET AL., "Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells," Cancer Immunology Immunotherapy, 1999, 48(1), 1-8  LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8), 483-470  SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598  GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	5		
BARCHI, J.J., JR., ET AL., "Synthesis and properties of carbohydrate- and glycopeptide-bearing nanoparticles," 226th Am. Chem. Soc., National Meeting, NY, Abstracts of Papers, 2003, Part 1, ISSN: 0065-7727, page 40  GLINSKY, V.V., ET AL., "Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium," Cancer Res., 2003, 63(13), 3805-3811  KHALDOYANIDI, S.K., ET AL., "MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions," 2003, 278(6), 4127-4134  RAGUPATHI G., ET AL., "Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells," Cancer Immunology Immunotherapy, 1999, 48(1), 1-8  LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8), 463-470  SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598  GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	6		
Am. Chem. Soc., National Meeting, NY, Abstracts of Papers, 2003, Part 1, ISSN: 0065-7727, page 40  GLINSKY, V.V., ET AL., "Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium," Cancer Res., 2003, 63(13), 3805-3811  KHALDOYANIDI, S.K., ET AL., "MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions," 2003, 278(6), 4127-4134  RAGUPATHI G., ET AL., "Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells," Cancer Immunology Immunotherapy, 1999, 48(1), 1-8  LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8), 463-470  SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598	7		
to the endothelium," Cancer Res., 2003, 63(13), 3805-3811    KHALDOYANIDI, S.K., ET AL., "MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions," 2003, 278(6), 4127-4134    RAGUPATHI G., ET AL., "Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells," Cancer Immunology Immunotherapy, 1999, 48(1), 1-8    LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8), 463-470    SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598    GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	8		
flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions," 2003, 278(6), 4127-4134  RAGUPATHI G., ET AL., "Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells," Cancer Immunology Immunotherapy, 1999, 48(1), 1-8  LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8), 463-470  SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598  GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	9		
cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells," Cancer Immunology Immunotherapy, 1999, 48(1), 1-8  LLOYD, K.O., "Carbohydrate vaccines for the immunotherapy of cancer," Drug News and Perspectives, 2000, 13(8), 463-470  SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598  GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	10		
SVAROVSKY, S.A., ET AL., "Synthesis of gold nanoparticles bearing the Themsen-Friedenreich disaccharide: a new multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598  GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	11	cyclohexane-1-carboxy 1 hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and	
multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2), 587-598  GAO, X., ET AL., "In vivo cancer targeting and imaging with semiconductor quantum dots," Nature Biotechnology,	12		
	13	multivalent presentation of an important tumor antigen," Tetrahedron: Asymmetry, Pergamon, Oxford, GB, 2005, 16(2),	
	14		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10578385		
Filing Date		2007-05-11		
First Named Inventor Josep		oh J. Barchi, Jr.		
Art Unit		1614		
Examiner Name	Not Y	et Assigned		
Attorney Docket Number		NIHA-0278		

	15	JAIN, R.K., ET AL. "Zooming in and out with quantum dots," Nature Biotechnology, 2004, 22(8), 959-960						
	16	American Chemical Society Division of Carbohydrate Chemistry, Newsletter, 2003, 1-17						
	17	BAEK, MG., ET AL. "Synthesis and antibody binding properties of glycodendrimers bearing the tumor related T-antigen," Chem. Commun., 2001, 257-258						
	18	FREIRE, T., ET AL., "Biochemical characterization of soluble Tn glycoproteins from malignant effusions of patients with carcinomas," Oncology Reports, 2003, 10, 1577-1585						
	19	GLINSKII, O.V., ET AL., "Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells," J. Physiol., 2003, 554.1, 89-99						
If you wis	h to ac	ld additi	ional non-patent literature document citation information please click the Add b	outton				
			EXAMINER SIGNATURE					
Examiner	Examiner Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.								